Xtant Medical Holdings Inc. (XTNT)
NYSE: XTNTHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XTNT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $29.49M
- EPS (TTM)
- -$0.11
- Dividend yield
- None
- 52-week range
- 0.17 – 0.84
- Day range
- 0.2016 – 0.2499
- Volume / Avg
- 257.13K / 1.69M
- Beta
- —
- Shares outstanding
- 140.45M
52-week range
XTNT stock today
Xtant Medical (XTNT) closed at $0.21 on Nov 20, down 2.82% (-$0.0061), versus the S&P 500's 3.70% decline. Trading was light, with 257.13K shares changing hands, about 15% of the average daily volume. At this level, XTNT sits near the bottom of its 52-week range of $0.17 to $0.84: 75.0% below the high, set on Dec 18, 2025 and 23.5% above the low.
XTNT is down 73.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 66.1%. Xtant Medical has posted a net loss over the last twelve months (EPS of -$0.11), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Xtant Medical
Company profileXtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Sean E. Browne
- Headquarters
- Belgrade, MT
- Employees
- 151
- Website
- xtantmedical.com
Financial highlights
Full financialsIn fiscal 2025, Xtant Medical generated $133.9 million in revenue, up 14.2% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $5.0 million, for a net margin of 3.7% versus a median of -13.2% in the prior 5 years. Gross margin was 62.9% (up from 58.2%) and operating margin 5.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $133.93M | $117.27M | $91.30M | $57.97M | $55.26M |
| Growth | +14.21% | +28.44% | +57.50% | +4.90% | +3.61% |
| Net income | $4.97M | $-16.45M | $660.00K | $-8.48M | $-4.85M |
| EPS (diluted) | $0.03 | $-0.12 | $0.01 | $-0.09 | $-0.06 |
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$1.03+390.48%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.03 vs —
XTNT news
All XTNT newsXtant Medical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NSPRInspireMD Inc. | 0.54 | -12.97% | $29.23M | vs XTNT |
| NEPHNephros Inc. | 2.61 | -8.10% | $28.37M | vs XTNT |
| TELATELA Bio Inc. | 0.6885 | -5.27% | $31.11M | vs XTNT |
| MDAISpectral AI Inc. Class A | 1.04 | -20.61% | $33.47M | vs XTNT |
| PLRZPolyrizon Ltd. | 9.31 | -8.42% | $22.61M | vs XTNT |
| DAVIDavion Healthcare Plc | 0.9001 | -9.99% | $22.50M | vs XTNT |
| SRTSSensus Healthcare Inc. | 2.26 | -4.24% | $37.20M | vs XTNT |
| PMIPicard Medical Inc. | 6.79 | +7.78% | $18.07M | vs XTNT |
Indexes, lists and sector
Xtant Medical stock FAQ
What is Xtant Medical's stock price today?
XTNT last traded at $0.21 as of Nov 20, 4:00 PM EST, down 2.82% on the day. Prices are delayed at least 15 minutes.
Does Xtant Medical pay a dividend?
No. Xtant Medical does not currently pay a regular cash dividend.
Who is Xtant Medical's CEO?
Mr. Sean E. Browne is the chief executive officer of Xtant Medical Holdings Inc., which has about 151 employees.
Has XTNT ever split its stock?
Yes. The most recent XTNT stock split was a 1-for-12 split on Feb 14, 2018, one of 2 splits on record.
What is the XTNT 52-week high?
The 52-week high for XTNT is $0.84 and the 52-week low is $0.17. The stock is currently 75.0% below its high.